Investigation Report on China Atorvastatin Market 2009-2018:Industry Trends, Size and Shares Research Report

ResearchMoz.us include new market research report" Investigation Report on China Atorvastatin Market 2009-2018 " to its huge collection of research reports.

The prevalence rate of abnormal blood lipid in China is lower than that in most developed countries, but the average serum TC level of Chinese people is upgrading for the economic development and lifestyle change. Meanwhile, diabetes and metabolic syndromes are very common in China.

View Full This Report With TOC @ http://www.researchmoz.us/investigation-report-on-china-atorvastatin-market-2009-2018-report.html

According to statistics, the prevalence rate of abnormal blood lipid is above 20% in the group aged at 18 or above. The total number of patients exceeds 200 million.

Blood lipid-lowering drugs performs better than the overall drug market and cardiovascular system drugs. The expanding rate of blood lipid-lowering drugs is obviously higher than that of cardiovascular system drugs and the proportion in the cardiovascular system drug market is increasing.

Atorvastatin, marketed by Pfizer as a calcium salt under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It works by inhibiting HMG-CoA reductase. In November 2011, Pfizer lost the patent protection in the USA. In May 2012, Pfizer lost the patent protection in the U.K. either. Liptor is the most popular drug of Pfizer with the accumulated sales value over USD 100 billion. It is the first drug with sales value breaking USD 100 billion in the history.

There are many enterprises producing APIs and finished products of atorvastatin. The market share of finished products is mainly occupied by Pfizer, which is above 80% by sales value every year. According to CRI's investigation, the CAGR of atorvastatin in China sample hospital market is above 40% during 2005-2013.

Browse All Latest Report Related to Pharmaceutical Research @...